Phototherapy in Persons With Multiple Sclerosis

Effect of UVB Phototherapy on Serum Vitamin D in Persons With Multiple Sclerosis; a Placebo Controlled Study

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02365259

Enrollment

Registered

2015-02-18

Start date

2015-01-31

Completion date

2016-02-29

Last updated

2015-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Brief summary

The current study examines the effect of phototherapy equipped with Narrow Band UVB lamps on vitamin D production in persons with MS.

Detailed description

Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.

Interventions

DEVICEPhototherapy

Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 64 Years

Healthy volunteers

Inclusion criteria

* Female with multiple sclerosis

Exclusion criteria

* Inability to stand still in a stabilized fashion without risk of falling for up to 6 minutes * Known medical history of calcium disorder or knowledge of high calcium levels * Known medical history of hyper-parathyroidism * Current supplementation with oral vitamin D * Known allergy to vitamin D * History of cancer of any type including but not limited to skin cancer * Obesity defined as BMI \> 30 * Known history of fat malabsorption conditions (i.e., steatorrhea) * Current use of anti-epileptic medication * Current use of glucocorticoids * Fitzpatrick skin types I and VI using the Fitzpatrick skin type analysis * Recent use of tanning facilities

Design outcomes

Primary

Measure	Time frame	Description
Change from Baseline in Serum Vitamin D at 4 and 8 weeks	0, 4, and 8 weeks	Venous blood will be collected to quantify levels of circulating Vitamin D.

Secondary

Measure	Time frame	Description
Change from Baseline in Walking Speed at 4 and 8 weeks	0, 4, and 8 weeks	Participants will walking for 25-feet as fast, but safely, as possible on an instrumented gait mat for measuring gait speed.
Change from Baseline in Cognitive Function at 4 and 8 weeks	0, 4, and 8 weeks	Participants will complete neuropsychological assessments of processing speed and learning and memory.
Change from Baseline in Mood State at 4 and 8 weeks	0, 4, and 8 weeks	Participants will complete a 30-item self-report measure of overall mood.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026